How Global Import Agent Can Help
Our peptide compliance specialists conduct comprehensive pre-launch label and claims reviews to prevent FDA enforcement action. We understand the complex regulatory boundaries between cosmetic peptides, dietary supplement ingredients, and prescription drug substances under current FDA interpretation.
Our service identifies potential violations of section 505(a) of the FD&C Act, evaluates intended use determinations under 21 CFR 201. 128, and ensures compliance with both FDA regulations and FTC advertising standards. We provide detailed remediation guidance and can serve as your Importer of Record following successful compliance certification.
Pre-launch label and website claims audit.
- FDA warning letter response and remediation support
- Import detention resolution for peptide products
- UK-US regulatory coordination and MHRA compliance
- Pre-Launch Compliance Audit – Complete label, website, and marketing materials review for FDA compliance before product launch
- Warning Letter Response – Expert remediation support for FDA enforcement actions with 15-day response timeline management
- Import Classification – Peptide product classification determination and regulatory pathway guidance for UK-US imports
FDA Peptide Enforcement Landscape
The FDA’s intensified enforcement against peptide therapeutic claims has created significant compliance challenges for importers. The March 2026 warning letter to Gram Peptides exemplifies this crackdown, citing violations for marketing Retatrutide and Tirzepatide with weight-loss claims as unapproved new drugs.
These enforcement actions demonstrate that peptide classification depends on intended use rather than molecular structure. Under Import Alert 54-15, peptide products making therapeutic claims face automatic detention at UK and US ports. The FDA’s intended use doctrine under 21 CFR 201.
128 means that marketing claims, not product formulation, determine regulatory classification. Companies importing research peptides or cosmetic peptides must carefully manage claims to avoid triggering prescription drug requirements under section 505(a) of the FD&C Act.
- Section 505(a) FD&C Act compliance assessment
- 21 CFR 201
- 128 intended use evaluation
- Import Alert 54-15 detention risk analysis
- FTC Section 5 advertising claim review
- DSHEA structure-function claim boundaries
What We Arrange And Manage End-To-End
1) Initial Compliance Assessment
Comprehensive review of product labels, websites, and marketing materials against current FDA enforcement priorities.
- Section 505(a) violation risk assessment
- Intended use determination under 21 CFR 201
- 128
- Import Alert 54-15 detention probability analysis
2) Regulatory Classification
Expert determination of appropriate regulatory pathway based on peptide structure, intended use, and marketing claims.
- Cosmetic peptide vs therapeutic peptide classification
- GRAS determination requirements for dietary supplements
- NDI notification necessity evaluation
3) Claims Remediation
Detailed guidance on compliant marketing language and required label modifications to prevent FDA enforcement action.
4) Pre-Import Clearance
Coordination with FDA and UK MHRA to ensure smooth customs clearance and avoid detention under peptide import alerts.
5) Ongoing Compliance Monitoring
Regular review of evolving FDA guidance and enforcement priorities to maintain compliant marketing and importation practices.
Complete Peptide Compliance Package
Label Review
Comprehensive FDA compliance audit of product labels and packaging materials.
Claims Analysis
FTC and FDA advertising claim evaluation with violation risk assessment.
Regulatory Classification
Expert determination of appropriate FDA regulatory pathway for peptide products.
Import Documentation
Proper customs documentation and FDA registration for compliant peptide imports.
Warning Letter Support
Expert remediation and response services for FDA enforcement actions.
Ongoing Monitoring
Regular compliance updates and regulatory change notifications for peptide importers.
What Is Peptide Label and Claims Review?
Peptide label and claims review is a pre-launch compliance service that evaluates product marketing materials against FDA and FTC regulations to prevent enforcement action. Following high-profile warning letters like the March 2026 Gram Peptides case, this service has become essential for peptide importers seeking to avoid costly recalls and legal remediation.
The service encompasses comprehensive evaluation of product labels, website content, and advertising materials against section 505(a) of the FD&C Act, intended use regulations under 21 CFR 201. 128, and FTC advertising standards.
Our experts identify potential violations before products reach market, providing cost-effective prevention versus expensive post-violation remediation. Before-you-ship checklist:
- Product labels reviewed for FDA compliance
- Website claims evaluated against FTC standards
- Regulatory classification determined
- Import documentation prepared
- Detention risk assessment completed
Our process:
- 48-hour compliance audit completion
- Detailed violation risk report delivery
- Remediation guidance implementation
- FDA coordination and clearance
- Ongoing compliance monitoring setup
Our specialists understand current peptide enforcement priorities, including the regulatory landscape following recent warning letters. We provide expert guidance on section 505(a) compliance and intended use determinations. Pre-launch compliance audits cost significantly less than post-violation remediation.
Our service prevents expensive warning letter responses, product recalls, and import detention resolution fees. Unique expertise in coordinating peptide imports between UK MHRA and US FDA requirements. We ensure compliance with both jurisdictions’ evolving peptide regulations and enforcement priorities.
Our expert compliance review prevents enforcement action before it occurs, saving significant remediation costs and protecting your business reputation.